The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Vikas Gupta; Claire Harrison; Elizabeth O. Hexner; Haifa Kathrin Al-Ali; Lynda Foltz; Michael Montgomery; William Sun; Prashanth Gopalakrishna; Hagop Kantarjian; Srdan Verstovsek

doi:10.3324/haematol.2016.151449

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Vikas Gupta, Claire Harrison, Elizabeth O. Hexner, Haifa Kathrin Al-Ali, Lynda Foltz, Michael Montgomery, William Sun, Prashanth Gopalakrishna, Hagop Kantarjian, Srdan Verstovsek

Leukemia

Research output: Contribution to journal › Letter › peer-review

49 Scopus citations

Original language	English (US)
Pages (from-to)	e482-e484
Journal	Haematologica
Volume	101
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2016.151449
State	Published - 2016

Keywords

Anemia
JAK inhibitor
Myelofibrosis
Overall survival
Ruxolitinib

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2016.151449

Cite this

@article{b1cf0c84da804140b6bc11774eae5ac5,

title = "The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies",

keywords = "Anemia, JAK inhibitor, Myelofibrosis, Overall survival, Ruxolitinib",

author = "Vikas Gupta and Claire Harrison and Hexner, {Elizabeth O.} and Al-Ali, {Haifa Kathrin} and Lynda Foltz and Michael Montgomery and William Sun and Prashanth Gopalakrishna and Hagop Kantarjian and Srdan Verstovsek",

note = "Funding Information: The COMFORT-I study (clinicaltrials.gov identifier:00952289) was sponsored by Incyte Corporation; the COMFORT-II study (clinicaltrials.gov identifier:00934544) was sponsored by Novartis Pharmaceuticals. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).",

year = "2016",

doi = "10.3324/haematol.2016.151449",

language = "English (US)",

volume = "101",

pages = "e482--e484",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

TY - JOUR

T1 - The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

AU - Gupta, Vikas

AU - Harrison, Claire

AU - Hexner, Elizabeth O.

AU - Al-Ali, Haifa Kathrin

AU - Foltz, Lynda

AU - Montgomery, Michael

AU - Sun, William

AU - Gopalakrishna, Prashanth

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

N1 - Funding Information: The COMFORT-I study (clinicaltrials.gov identifier:00952289) was sponsored by Incyte Corporation; the COMFORT-II study (clinicaltrials.gov identifier:00934544) was sponsored by Novartis Pharmaceuticals. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

PY - 2016

Y1 - 2016

KW - Anemia

KW - JAK inhibitor

KW - Myelofibrosis

KW - Overall survival

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85002412628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002412628&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.151449

DO - 10.3324/haematol.2016.151449

M3 - Letter

C2 - 27587385

AN - SCOPUS:85002412628

SN - 0390-6078

VL - 101

SP - e482-e484

JO - Haematologica

JF - Haematologica

IS - 12

ER -

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this